Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 1,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,500 shares of the stock in a transaction dated Thursday, September 26th. The stock was purchased at an average price of $14.63 per share, for a total transaction of $21,945.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,536,102 shares in the company, valued at approximately $80,993,172.26. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Monday, August 5th, Snehal Patel purchased 5,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $13.18 per share, for a total transaction of $72,490.00.
• On Tuesday, July 23rd, Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $15.89 per share, for a total transaction of $23,835.00.

Greenwich LifeSciences Stock Performance

NASDAQ:GLSI opened at $13.97 on Thursday. The company’s 50-day simple moving average is $14.36 and its 200-day simple moving average is $15.01. The stock has a market capitalization of $179.93 million, a P/E ratio of -19.40 and a beta of 1.61. Greenwich LifeSciences, Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $21.44.

Greenwich LifeSciences (NASDAQ:GLSI) last released its earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). On average, research analysts forecast that Greenwich LifeSciences, Inc. will post -0.81 EPS for the current year.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers acquired a new stake in Greenwich LifeSciences in the 2nd quarter worth approximately $117,000. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter worth approximately $264,000. Finally, Vanguard Group Inc. boosted its stake in Greenwich LifeSciences by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after purchasing an additional 1,420 shares in the last quarter. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their price target on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, August 23rd.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.